Xention Limited-Product Pipeline Review-2015

Xention Limited-Product Pipeline Review-2015

  • Products Id :- GMDHC07460CDB
  • |
  • Pages: 29
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Xention Limited-Product Pipeline Review-2015


Global Markets Direct's, 'Xention Limited-Product Pipeline Review-2015', provides an overview of the Xention Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Xention Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Xention Limited including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Xention Limited's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Xention Limited's pipeline products

Reasons To Buy

Evaluate Xention Limited's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Xention Limited in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Xention Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Xention Limited and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Xention Limited

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Xention Limited and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Xention Limited Snapshot 5

Xention Limited Overview 5

Key Information 5

Key Facts 5

Xention Limited-Research and Development Overview 6

Key Therapeutic Areas 6

Xention Limited-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Out-Licensed Products 10

Out-Licensed Products/Combination Treatment Modalities 11

Xention Limited-Pipeline Products Glance 12

Xention Limited-Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Xention Limited-Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 14

Xention Limited-Drug Profiles 15

XEND-0103 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

XEN-R0702 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

XENR-0703 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

XENR-0706 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Xention Limited-Pipeline Analysis 21

Xention Limited-Pipeline Products by Target 21

Xention Limited-Pipeline Products by Route of Administration 22

Xention Limited-Pipeline Products by Molecule Type 23

Xention Limited-Pipeline Products by Mechanism of Action 24

Xention Limited-Recent Pipeline Updates 25

Xention Limited-Dormant Projects 26

Xention Limited-Locations And Subsidiaries 27

Head Office 27

Appendix 28

Methodology 28

Coverage 28

Secondary Research 28

Primary Research 28

Expert Panel Validation 28

Contact Us 28

Disclaimer 29

List of Tables

Xention Limited, Key Information 5

Xention Limited, Key Facts 5

Xention Limited-Pipeline by Indication, 2015 7

Xention Limited-Pipeline by Stage of Development, 2015 8

Xention Limited-Monotherapy Products in Pipeline, 2015 9

Xention Limited-Out-Licensed Products in Pipeline, 2015 10

Xention Limited-Out-Licensed Products/ Combination Treatment Modalities, 2015 11

Xention Limited-Phase II, 2015 12

Xention Limited-Preclinical, 2015 13

Xention Limited-Discovery, 2015 14

Xention Limited-Pipeline by Target, 2015 21

Xention Limited-Pipeline by Route of Administration, 2015 22

Xention Limited-Pipeline by Molecule Type, 2015 23

Xention Limited-Pipeline Products by Mechanism of Action, 2015 24

Xention Limited-Recent Pipeline Updates, 2015 25

Xention Limited-Dormant Developmental Projects,2015 26

List of Figures

Xention Limited-Pipeline by Stage of Development, 2015 8

Xention Limited-Monotherapy Products in Pipeline, 2015 9

Xention Limited-Pipeline by Top 10 Target, 2015 21

Xention Limited-Pipeline by Top 10 Route of Administration, 2015 22

Xention Limited-Pipeline by Top 10 Molecule Type, 2015 23

Xention Limited-Pipeline Products by Top 10 Mechanism of Action, 2015 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of Xention Limited; Xention Limited - Key Therapeutics; Xention Limited - Pipeline Overview and Promising Molecules; Xention Limited - News; Xention Limited - Latest Updates; Xention Limited - Pipeline; Xention Limited - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102450
Site License
USD 3000 INR 204900
Corporate User License
USD 4500 INR 307350



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com